What is the projected market valuation of the Veterinary Oncology Market by 2035?

The Veterinary Oncology Market is projected to reach a valuation of 1.99 USD Billion by 2035. Read More

What was the market valuation of the Veterinary Oncology Market in 2024?

In 2024, the Veterinary Oncology Market was valued at 0.9147 USD Billion. Read More

What is the expected CAGR for the Veterinary Oncology Market during the forecast period 2025 - 2035?

The expected CAGR for the Veterinary Oncology Market during the forecast period 2025 - 2035 is 7.32%. Read More

Which companies are considered key players in the Veterinary Oncology Market?

Key players in the Veterinary Oncology Market include VCA Inc, Mars Petcare, Boehringer Ingelheim, Zoetis Inc, and Elanco Animal Health. Read More

What are the primary segments of the Veterinary Oncology Market?

The primary segments of the Veterinary Oncology Market include Oncology Type, Animal Type, Service Type, End User, and Diagnostic Method. Read More

How much is the Surgery segment expected to generate by 2035?

The Surgery segment is expected to generate between 0.45 and 0.9 USD Billion by 2035. Read More

What is the projected revenue for the Chemotherapy segment by 2035?

The Chemotherapy segment is projected to generate between 0.55 and 1.1 USD Billion by 2035. Read More

What is the expected market size for the Treatment service type by 2035?

The Treatment service type is expected to reach a market size of between 0.9 and 1.8 USD Billion by 2035. Read More

Which animal type is anticipated to dominate the Veterinary Oncology Market?

Dogs are anticipated to dominate the Veterinary Oncology Market, with a projected revenue of between 0.9 and 1.8 USD Billion by 2035. Read More

What is the expected revenue for Imaging Techniques in the Diagnostic Method segment by 2035?

The Imaging Techniques in the Diagnostic Method segment is expected to generate between 0.65 and 1.3 USD Billion by 2035. Read More

Veterinary Oncology Market

ID: MRFR/Pharma/31467-HCR

128 Pages

Nidhi Mandole

Last Updated: May 15, 2026

Veterinary Oncology Market Research Report: Size, Share, Trend Analysis By Oncology Type (Surgery, Radiation Therapy, Chemotherapy, Immunotherapy, Targeted Therapy), By Animal Type (Dogs, Cats, Horses, Small Mammals, Exotic Animals), By Service Type (Diagnosis, Treatment, Palliative Care, Preventive Care), By End Users (Veterinary Clinics, Animal Hospitals, Research Institutions), By Diagnostic Method (Biopsy, Blood Tests, Imaging Techniques, Endoscopy) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Summary Table of Contents Segmentation Methodology Download PDF

SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
1. 1.1 EXECUTIVE SUMMARY | |
  1. 1.1.1 Market Overview | |
  2. 1.1.2 Key Findings | |
  3. 1.1.3 Market Segmentation | |
  4. 1.1.4 Competitive Landscape | |
  5. 1.1.5 Challenges and Opportunities | |
  6. 1.1.6 Future Outlook 2
SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
1. 2.1 MARKET INTRODUCTION | |
  1. 2.1.1 Definition | |
  2. 2.1.2 Scope of the study | | |
    1. 2.1.2.1 Research Objective | | |
    2. 2.1.2.2 Assumption | | |
    3. 2.1.2.3 Limitations |
2. 2.2 RESEARCH METHODOLOGY | |
  1. 2.2.1 Overview | |
  2. 2.2.2 Data Mining | |
  3. 2.2.3 Secondary Research | |
  4. 2.2.4 Primary Research | | |
    1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
    2. 2.2.4.2 Breakdown of Primary Respondents | |
  5. 2.2.5 Forecasting Model | |
  6. 2.2.6 Market Size Estimation | | |
    1. 2.2.6.1 Bottom-Up Approach | | |
    2. 2.2.6.2 Top-Down Approach | |
  7. 2.2.7 Data Triangulation | |
  8. 2.2.8 Validation 3
SECTION III: QUALITATIVE ANALYSIS |
1. 3.1 MARKET DYNAMICS | |
  1. 3.1.1 Overview | |
  2. 3.1.2 Drivers | |
  3. 3.1.3 Restraints | |
  4. 3.1.4 Opportunities |
2. 3.2 MARKET FACTOR ANALYSIS | |
  1. 3.2.1 Value chain Analysis | |
  2. 3.2.2 Porter's Five Forces Analysis | | |
    1. 3.2.2.1 Bargaining Power of Suppliers | | |
    2. 3.2.2.2 Bargaining Power of Buyers | | |
    3. 3.2.2.3 Threat of New Entrants | | |
    4. 3.2.2.4 Threat of Substitutes | | |
    5. 3.2.2.5 Intensity of Rivalry | |
  3. 3.2.3 COVID-19 Impact Analysis | | |
    1. 3.2.3.1 Market Impact Analysis | | |
    2. 3.2.3.2 Regional Impact | | |
    3. 3.2.3.3 Opportunity and Threat Analysis 4
SECTION IV: QUANTITATIVE ANALYSIS |
1. 4.1 Healthcare, BY Oncology Type (USD Billion) | |
  1. 4.1.1 Surgery | |
  2. 4.1.2 Radiation Therapy | |
  3. 4.1.3 Chemotherapy | |
  4. 4.1.4 Immunotherapy | |
  5. 4.1.5 Targeted Therapy |
2. 4.2 Healthcare, BY Animal Type (USD Billion) | |
  1. 4.2.1 Dogs | |
  2. 4.2.2 Cats | |
  3. 4.2.3 Horses | |
  4. 4.2.4 Small Mammals | |
  5. 4.2.5 Exotic Animals |
3. 4.3 Healthcare, BY Service Type (USD Billion) | |
  1. 4.3.1 Diagnosis | |
  2. 4.3.2 Treatment | |
  3. 4.3.3 Palliative Care | |
  4. 4.3.4 Preventive Care |
4. 4.4 Healthcare, BY End User (USD Billion) | |
  1. 4.4.1 Veterinary Clinics | |
  2. 4.4.2 Animal Hospitals | |
  3. 4.4.3 Research Institutions |
5. 4.5 Healthcare, BY Diagnostic Method (USD Billion) | |
  1. 4.5.1 Biopsy | |
  2. 4.5.2 Blood Tests | |
  3. 4.5.3 Imaging Techniques | |
  4. 4.5.4 Endoscopy |
6. 4.6 Healthcare, BY Region (USD Billion) | |
  1. 4.6.1 North America | | |
    1. 4.6.1.1 US | | |
    2. 4.6.1.2 Canada | |
  2. 4.6.2 Europe | | |
    1. 4.6.2.1 Germany | | |
    2. 4.6.2.2 UK | | |
    3. 4.6.2.3 France | | |
    4. 4.6.2.4 Russia | | |
    5. 4.6.2.5 Italy | | |
    6. 4.6.2.6 Spain | | |
    7. 4.6.2.7 Rest of Europe | |
  3. 4.6.3 APAC | | |
    1. 4.6.3.1 China | | |
    2. 4.6.3.2 India | | |
    3. 4.6.3.3 Japan | | |
    4. 4.6.3.4 South Korea | | |
    5. 4.6.3.5 Malaysia | | |
    6. 4.6.3.6 Thailand | | |
    7. 4.6.3.7 Indonesia | | |
    8. 4.6.3.8 Rest of APAC | |
  4. 4.6.4 South America | | |
    1. 4.6.4.1 Brazil | | |
    2. 4.6.4.2 Mexico | | |
    3. 4.6.4.3 Argentina | | |
    4. 4.6.4.4 Rest of South America | |
  5. 4.6.5 MEA | | |
    1. 4.6.5.1 GCC Countries | | |
    2. 4.6.5.2 South Africa | | |
    3. 4.6.5.3 Rest of MEA 5
SECTION V: COMPETITIVE ANALYSIS |
1. 5.1 Competitive Landscape | |
  1. 5.1.1 Overview | |
  2. 5.1.2 Competitive Analysis | |
  3. 5.1.3 Market share Analysis | |
  4. 5.1.4 Major Growth Strategy in the Healthcare | |
  5. 5.1.5 Competitive Benchmarking | |
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
  7. 5.1.7 Key developments and growth strategies | | |
    1. 5.1.7.1 New Product Launch/Service Deployment | | |
    2. 5.1.7.2 Merger & Acquisitions | | |
    3. 5.1.7.3 Joint Ventures | |
  8. 5.1.8 Major Players Financial Matrix | | |
    1. 5.1.8.1 Sales and Operating Income | | |
    2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
2. 5.2 Company Profiles | |
  1. 5.2.1 VCA Inc (US) | | |
    1. 5.2.1.1 Financial Overview | | |
    2. 5.2.1.2 Products Offered | | |
    3. 5.2.1.3 Key Developments | | |
    4. 5.2.1.4 SWOT Analysis | | |
    5. 5.2.1.5 Key Strategies | |
  2. 5.2.2 Mars Petcare (US) | | |
    1. 5.2.2.1 Financial Overview | | |
    2. 5.2.2.2 Products Offered | | |
    3. 5.2.2.3 Key Developments | | |
    4. 5.2.2.4 SWOT Analysis | | |
    5. 5.2.2.5 Key Strategies | |
  3. 5.2.3 Boehringer Ingelheim (DE) | | |
    1. 5.2.3.1 Financial Overview | | |
    2. 5.2.3.2 Products Offered | | |
    3. 5.2.3.3 Key Developments | | |
    4. 5.2.3.4 SWOT Analysis | | |
    5. 5.2.3.5 Key Strategies | |
  4. 5.2.4 Zoetis Inc (US) | | |
    1. 5.2.4.1 Financial Overview | | |
    2. 5.2.4.2 Products Offered | | |
    3. 5.2.4.3 Key Developments | | |
    4. 5.2.4.4 SWOT Analysis | | |
    5. 5.2.4.5 Key Strategies | |
  5. 5.2.5 Elanco Animal Health (US) | | |
    1. 5.2.5.1 Financial Overview | | |
    2. 5.2.5.2 Products Offered | | |
    3. 5.2.5.3 Key Developments | | |
    4. 5.2.5.4 SWOT Analysis | | |
    5. 5.2.5.5 Key Strategies | |
  6. 5.2.6 Ceva Santé Animale (FR) | | |
    1. 5.2.6.1 Financial Overview | | |
    2. 5.2.6.2 Products Offered | | |
    3. 5.2.6.3 Key Developments | | |
    4. 5.2.6.4 SWOT Analysis | | |
    5. 5.2.6.5 Key Strategies | |
  7. 5.2.7 MediVet (AU) | | |
    1. 5.2.7.1 Financial Overview | | |
    2. 5.2.7.2 Products Offered | | |
    3. 5.2.7.3 Key Developments | | |
    4. 5.2.7.4 SWOT Analysis | | |
    5. 5.2.7.5 Key Strategies | |
  8. 5.2.8 VetDC (US) | | |
    1. 5.2.8.1 Financial Overview | | |
    2. 5.2.8.2 Products Offered | | |
    3. 5.2.8.3 Key Developments | | |
    4. 5.2.8.4 SWOT Analysis | | |
    5. 5.2.8.5 Key Strategies | |
  9. 5.2.9 OncoPet (US) | | |
    1. 5.2.9.1 Financial Overview | | |
    2. 5.2.9.2 Products Offered | | |
    3. 5.2.9.3 Key Developments | | |
    4. 5.2.9.4 SWOT Analysis | | |
    5. 5.2.9.5 Key Strategies |
3. 5.3 Appendix | |
  1. 5.3.1 References | |
  2. 5.3.2 Related Reports 6 LIST OF FIGURES |
4. 6.1 MARKET SYNOPSIS |
5. 6.2 NORTH AMERICA MARKET ANALYSIS |
6. 6.3 US MARKET ANALYSIS BY ONCOLOGY TYPE |
7. 6.4 US MARKET ANALYSIS BY ANIMAL TYPE |
8. 6.5 US MARKET ANALYSIS BY SERVICE TYPE |
9. 6.6 US MARKET ANALYSIS BY END USER |
10. 6.7 US MARKET ANALYSIS BY DIAGNOSTIC METHOD |
11. 6.8 CANADA MARKET ANALYSIS BY ONCOLOGY TYPE |
12. 6.9 CANADA MARKET ANALYSIS BY ANIMAL TYPE |
13. 6.10 CANADA MARKET ANALYSIS BY SERVICE TYPE |
14. 6.11 CANADA MARKET ANALYSIS BY END USER |
15. 6.12 CANADA MARKET ANALYSIS BY DIAGNOSTIC METHOD |
16. 6.13 EUROPE MARKET ANALYSIS |
17. 6.14 GERMANY MARKET ANALYSIS BY ONCOLOGY TYPE |
18. 6.15 GERMANY MARKET ANALYSIS BY ANIMAL TYPE |
19. 6.16 GERMANY MARKET ANALYSIS BY SERVICE TYPE |
20. 6.17 GERMANY MARKET ANALYSIS BY END USER |
21. 6.18 GERMANY MARKET ANALYSIS BY DIAGNOSTIC METHOD |
22. 6.19 UK MARKET ANALYSIS BY ONCOLOGY TYPE |
23. 6.20 UK MARKET ANALYSIS BY ANIMAL TYPE |
24. 6.21 UK MARKET ANALYSIS BY SERVICE TYPE |
25. 6.22 UK MARKET ANALYSIS BY END USER |
26. 6.23 UK MARKET ANALYSIS BY DIAGNOSTIC METHOD |
27. 6.24 FRANCE MARKET ANALYSIS BY ONCOLOGY TYPE |
28. 6.25 FRANCE MARKET ANALYSIS BY ANIMAL TYPE |
29. 6.26 FRANCE MARKET ANALYSIS BY SERVICE TYPE |
30. 6.27 FRANCE MARKET ANALYSIS BY END USER |
31. 6.28 FRANCE MARKET ANALYSIS BY DIAGNOSTIC METHOD |
32. 6.29 RUSSIA MARKET ANALYSIS BY ONCOLOGY TYPE |
33. 6.30 RUSSIA MARKET ANALYSIS BY ANIMAL TYPE |
34. 6.31 RUSSIA MARKET ANALYSIS BY SERVICE TYPE |
35. 6.32 RUSSIA MARKET ANALYSIS BY END USER |
36. 6.33 RUSSIA MARKET ANALYSIS BY DIAGNOSTIC METHOD |
37. 6.34 ITALY MARKET ANALYSIS BY ONCOLOGY TYPE |
38. 6.35 ITALY MARKET ANALYSIS BY ANIMAL TYPE |
39. 6.36 ITALY MARKET ANALYSIS BY SERVICE TYPE |
40. 6.37 ITALY MARKET ANALYSIS BY END USER |
41. 6.38 ITALY MARKET ANALYSIS BY DIAGNOSTIC METHOD |
42. 6.39 SPAIN MARKET ANALYSIS BY ONCOLOGY TYPE |
43. 6.40 SPAIN MARKET ANALYSIS BY ANIMAL TYPE |
44. 6.41 SPAIN MARKET ANALYSIS BY SERVICE TYPE |
45. 6.42 SPAIN MARKET ANALYSIS BY END USER |
46. 6.43 SPAIN MARKET ANALYSIS BY DIAGNOSTIC METHOD |
47. 6.44 REST OF EUROPE MARKET ANALYSIS BY ONCOLOGY TYPE |
48. 6.45 REST OF EUROPE MARKET ANALYSIS BY ANIMAL TYPE |
49. 6.46 REST OF EUROPE MARKET ANALYSIS BY SERVICE TYPE |
50. 6.47 REST OF EUROPE MARKET ANALYSIS BY END USER |
51. 6.48 REST OF EUROPE MARKET ANALYSIS BY DIAGNOSTIC METHOD |
52. 6.49 APAC MARKET ANALYSIS |
53. 6.50 CHINA MARKET ANALYSIS BY ONCOLOGY TYPE |
54. 6.51 CHINA MARKET ANALYSIS BY ANIMAL TYPE |
55. 6.52 CHINA MARKET ANALYSIS BY SERVICE TYPE |
56. 6.53 CHINA MARKET ANALYSIS BY END USER |
57. 6.54 CHINA MARKET ANALYSIS BY DIAGNOSTIC METHOD |
58. 6.55 INDIA MARKET ANALYSIS BY ONCOLOGY TYPE |
59. 6.56 INDIA MARKET ANALYSIS BY ANIMAL TYPE |
60. 6.57 INDIA MARKET ANALYSIS BY SERVICE TYPE |
61. 6.58 INDIA MARKET ANALYSIS BY END USER |
62. 6.59 INDIA MARKET ANALYSIS BY DIAGNOSTIC METHOD |
63. 6.60 JAPAN MARKET ANALYSIS BY ONCOLOGY TYPE |
64. 6.61 JAPAN MARKET ANALYSIS BY ANIMAL TYPE |
65. 6.62 JAPAN MARKET ANALYSIS BY SERVICE TYPE |
66. 6.63 JAPAN MARKET ANALYSIS BY END USER |
67. 6.64 JAPAN MARKET ANALYSIS BY DIAGNOSTIC METHOD |
68. 6.65 SOUTH KOREA MARKET ANALYSIS BY ONCOLOGY TYPE |
69. 6.66 SOUTH KOREA MARKET ANALYSIS BY ANIMAL TYPE |
70. 6.67 SOUTH KOREA MARKET ANALYSIS BY SERVICE TYPE |
71. 6.68 SOUTH KOREA MARKET ANALYSIS BY END USER |
72. 6.69 SOUTH KOREA MARKET ANALYSIS BY DIAGNOSTIC METHOD |
73. 6.70 MALAYSIA MARKET ANALYSIS BY ONCOLOGY TYPE |
74. 6.71 MALAYSIA MARKET ANALYSIS BY ANIMAL TYPE |
75. 6.72 MALAYSIA MARKET ANALYSIS BY SERVICE TYPE |
76. 6.73 MALAYSIA MARKET ANALYSIS BY END USER |
77. 6.74 MALAYSIA MARKET ANALYSIS BY DIAGNOSTIC METHOD |
78. 6.75 THAILAND MARKET ANALYSIS BY ONCOLOGY TYPE |
79. 6.76 THAILAND MARKET ANALYSIS BY ANIMAL TYPE |
80. 6.77 THAILAND MARKET ANALYSIS BY SERVICE TYPE |
81. 6.78 THAILAND MARKET ANALYSIS BY END USER |
82. 6.79 THAILAND MARKET ANALYSIS BY DIAGNOSTIC METHOD |
83. 6.80 INDONESIA MARKET ANALYSIS BY ONCOLOGY TYPE |
84. 6.81 INDONESIA MARKET ANALYSIS BY ANIMAL TYPE |
85. 6.82 INDONESIA MARKET ANALYSIS BY SERVICE TYPE |
86. 6.83 INDONESIA MARKET ANALYSIS BY END USER |
87. 6.84 INDONESIA MARKET ANALYSIS BY DIAGNOSTIC METHOD |
88. 6.85 REST OF APAC MARKET ANALYSIS BY ONCOLOGY TYPE |
89. 6.86 REST OF APAC MARKET ANALYSIS BY ANIMAL TYPE |
90. 6.87 REST OF APAC MARKET ANALYSIS BY SERVICE TYPE |
91. 6.88 REST OF APAC MARKET ANALYSIS BY END USER |
92. 6.89 REST OF APAC MARKET ANALYSIS BY DIAGNOSTIC METHOD |
93. 6.90 SOUTH AMERICA MARKET ANALYSIS |
94. 6.91 BRAZIL MARKET ANALYSIS BY ONCOLOGY TYPE |
95. 6.92 BRAZIL MARKET ANALYSIS BY ANIMAL TYPE |
96. 6.93 BRAZIL MARKET ANALYSIS BY SERVICE TYPE |
97. 6.94 BRAZIL MARKET ANALYSIS BY END USER |
98. 6.95 BRAZIL MARKET ANALYSIS BY DIAGNOSTIC METHOD |
99. 6.96 MEXICO MARKET ANALYSIS BY ONCOLOGY TYPE |
100. 6.97 MEXICO MARKET ANALYSIS BY ANIMAL TYPE |
101. 6.98 MEXICO MARKET ANALYSIS BY SERVICE TYPE |
102. 6.99 MEXICO MARKET ANALYSIS BY END USER |
103. 6.100 MEXICO MARKET ANALYSIS BY DIAGNOSTIC METHOD |
104. 6.101 ARGENTINA MARKET ANALYSIS BY ONCOLOGY TYPE |
105. 6.102 ARGENTINA MARKET ANALYSIS BY ANIMAL TYPE |
106. 6.103 ARGENTINA MARKET ANALYSIS BY SERVICE TYPE |
107. 6.104 ARGENTINA MARKET ANALYSIS BY END USER |
108. 6.105 ARGENTINA MARKET ANALYSIS BY DIAGNOSTIC METHOD |
109. 6.106 REST OF SOUTH AMERICA MARKET ANALYSIS BY ONCOLOGY TYPE |
110. 6.107 REST OF SOUTH AMERICA MARKET ANALYSIS BY ANIMAL TYPE |
111. 6.108 REST OF SOUTH AMERICA MARKET ANALYSIS BY SERVICE TYPE |
112. 6.109 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USER |
113. 6.110 REST OF SOUTH AMERICA MARKET ANALYSIS BY DIAGNOSTIC METHOD |
114. 6.111 MEA MARKET ANALYSIS |
115. 6.112 GCC COUNTRIES MARKET ANALYSIS BY ONCOLOGY TYPE |
116. 6.113 GCC COUNTRIES MARKET ANALYSIS BY ANIMAL TYPE |
117. 6.114 GCC COUNTRIES MARKET ANALYSIS BY SERVICE TYPE |
118. 6.115 GCC COUNTRIES MARKET ANALYSIS BY END USER |
119. 6.116 GCC COUNTRIES MARKET ANALYSIS BY DIAGNOSTIC METHOD |
120. 6.117 SOUTH AFRICA MARKET ANALYSIS BY ONCOLOGY TYPE |
121. 6.118 SOUTH AFRICA MARKET ANALYSIS BY ANIMAL TYPE |
122. 6.119 SOUTH AFRICA MARKET ANALYSIS BY SERVICE TYPE |
123. 6.120 SOUTH AFRICA MARKET ANALYSIS BY END USER |
124. 6.121 SOUTH AFRICA MARKET ANALYSIS BY DIAGNOSTIC METHOD |
125. 6.122 REST OF MEA MARKET ANALYSIS BY ONCOLOGY TYPE |
126. 6.123 REST OF MEA MARKET ANALYSIS BY ANIMAL TYPE |
127. 6.124 REST OF MEA MARKET ANALYSIS BY SERVICE TYPE |
128. 6.125 REST OF MEA MARKET ANALYSIS BY END USER |
129. 6.126 REST OF MEA MARKET ANALYSIS BY DIAGNOSTIC METHOD |
130. 6.127 KEY BUYING CRITERIA OF HEALTHCARE |
131. 6.128 RESEARCH PROCESS OF MRFR |
132. 6.129 DRO ANALYSIS OF HEALTHCARE |
133. 6.130 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
134. 6.131 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
135. 6.132 SUPPLY / VALUE CHAIN: HEALTHCARE |
136. 6.133 HEALTHCARE, BY ONCOLOGY TYPE, 2024 (% SHARE) |
137. 6.134 HEALTHCARE, BY ONCOLOGY TYPE, 2024 TO 2035 (USD Billion) |
138. 6.135 HEALTHCARE, BY ANIMAL TYPE, 2024 (% SHARE) |
139. 6.136 HEALTHCARE, BY ANIMAL TYPE, 2024 TO 2035 (USD Billion) |
140. 6.137 HEALTHCARE, BY SERVICE TYPE, 2024 (% SHARE) |
141. 6.138 HEALTHCARE, BY SERVICE TYPE, 2024 TO 2035 (USD Billion) |
142. 6.139 HEALTHCARE, BY END USER, 2024 (% SHARE) |
143. 6.140 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Billion) |
144. 6.141 HEALTHCARE, BY DIAGNOSTIC METHOD, 2024 (% SHARE) |
145. 6.142 HEALTHCARE, BY DIAGNOSTIC METHOD, 2024 TO 2035 (USD Billion) |
146. 6.143 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
147. 7.1 LIST OF ASSUMPTIONS | |
  1. 7.1.1 |
148. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.2.1 BY ONCOLOGY TYPE, 2025-2035 (USD Billion) | |
  2. 7.2.2 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
  3. 7.2.3 BY SERVICE TYPE, 2025-2035 (USD Billion) | |
  4. 7.2.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.2.5 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) |
149. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.3.1 BY ONCOLOGY TYPE, 2025-2035 (USD Billion) | |
  2. 7.3.2 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
  3. 7.3.3 BY SERVICE TYPE, 2025-2035 (USD Billion) | |
  4. 7.3.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.3.5 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) |
150. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.4.1 BY ONCOLOGY TYPE, 2025-2035 (USD Billion) | |
  2. 7.4.2 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
  3. 7.4.3 BY SERVICE TYPE, 2025-2035 (USD Billion) | |
  4. 7.4.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.4.5 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) |
151. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.5.1 BY ONCOLOGY TYPE, 2025-2035 (USD Billion) | |
  2. 7.5.2 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
  3. 7.5.3 BY SERVICE TYPE, 2025-2035 (USD Billion) | |
  4. 7.5.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.5.5 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) |
152. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.6.1 BY ONCOLOGY TYPE, 2025-2035 (USD Billion) | |
  2. 7.6.2 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
  3. 7.6.3 BY SERVICE TYPE, 2025-2035 (USD Billion) | |
  4. 7.6.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.6.5 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) |
153. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.7.1 BY ONCOLOGY TYPE, 2025-2035 (USD Billion) | |
  2. 7.7.2 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
  3. 7.7.3 BY SERVICE TYPE, 2025-2035 (USD Billion) | |
  4. 7.7.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.7.5 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) |
154. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.8.1 BY ONCOLOGY TYPE, 2025-2035 (USD Billion) | |
  2. 7.8.2 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
  3. 7.8.3 BY SERVICE TYPE, 2025-2035 (USD Billion) | |
  4. 7.8.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.8.5 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) |
155. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.9.1 BY ONCOLOGY TYPE, 2025-2035 (USD Billion) | |
  2. 7.9.2 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
  3. 7.9.3 BY SERVICE TYPE, 2025-2035 (USD Billion) | |
  4. 7.9.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.9.5 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) |
156. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.10.1 BY ONCOLOGY TYPE, 2025-2035 (USD Billion) | |
  2. 7.10.2 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
  3. 7.10.3 BY SERVICE TYPE, 2025-2035 (USD Billion) | |
  4. 7.10.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.10.5 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) |
157. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.11.1 BY ONCOLOGY TYPE, 2025-2035 (USD Billion) | |
  2. 7.11.2 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
  3. 7.11.3 BY SERVICE TYPE, 2025-2035 (USD Billion) | |
  4. 7.11.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.11.5 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) |
158. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.12.1 BY ONCOLOGY TYPE, 2025-2035 (USD Billion) | |
  2. 7.12.2 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
  3. 7.12.3 BY SERVICE TYPE, 2025-2035 (USD Billion) | |
  4. 7.12.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.12.5 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) |
159. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.13.1 BY ONCOLOGY TYPE, 2025-2035 (USD Billion) | |
  2. 7.13.2 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
  3. 7.13.3 BY SERVICE TYPE, 2025-2035 (USD Billion) | |
  4. 7.13.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.13.5 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) |
160. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.14.1 BY ONCOLOGY TYPE, 2025-2035 (USD Billion) | |
  2. 7.14.2 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
  3. 7.14.3 BY SERVICE TYPE, 2025-2035 (USD Billion) | |
  4. 7.14.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.14.5 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) |
161. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.15.1 BY ONCOLOGY TYPE, 2025-2035 (USD Billion) | |
  2. 7.15.2 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
  3. 7.15.3 BY SERVICE TYPE, 2025-2035 (USD Billion) | |
  4. 7.15.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.15.5 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) |
162. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.16.1 BY ONCOLOGY TYPE, 2025-2035 (USD Billion) | |
  2. 7.16.2 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
  3. 7.16.3 BY SERVICE TYPE, 2025-2035 (USD Billion) | |
  4. 7.16.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.16.5 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) |
163. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.17.1 BY ONCOLOGY TYPE, 2025-2035 (USD Billion) | |
  2. 7.17.2 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
  3. 7.17.3 BY SERVICE TYPE, 2025-2035 (USD Billion) | |
  4. 7.17.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.17.5 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) |
164. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.18.1 BY ONCOLOGY TYPE, 2025-2035 (USD Billion) | |
  2. 7.18.2 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
  3. 7.18.3 BY SERVICE TYPE, 2025-2035 (USD Billion) | |
  4. 7.18.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.18.5 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) |
165. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.19.1 BY ONCOLOGY TYPE, 2025-2035 (USD Billion) | |
  2. 7.19.2 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
  3. 7.19.3 BY SERVICE TYPE, 2025-2035 (USD Billion) | |
  4. 7.19.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.19.5 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) |
166. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.20.1 BY ONCOLOGY TYPE, 2025-2035 (USD Billion) | |
  2. 7.20.2 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
  3. 7.20.3 BY SERVICE TYPE, 2025-2035 (USD Billion) | |
  4. 7.20.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.20.5 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) |
167. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.21.1 BY ONCOLOGY TYPE, 2025-2035 (USD Billion) | |
  2. 7.21.2 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
  3. 7.21.3 BY SERVICE TYPE, 2025-2035 (USD Billion) | |
  4. 7.21.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.21.5 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) |
168. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.22.1 BY ONCOLOGY TYPE, 2025-2035 (USD Billion) | |
  2. 7.22.2 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
  3. 7.22.3 BY SERVICE TYPE, 2025-2035 (USD Billion) | |
  4. 7.22.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.22.5 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) |
169. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.23.1 BY ONCOLOGY TYPE, 2025-2035 (USD Billion) | |
  2. 7.23.2 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
  3. 7.23.3 BY SERVICE TYPE, 2025-2035 (USD Billion) | |
  4. 7.23.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.23.5 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) |
170. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.24.1 BY ONCOLOGY TYPE, 2025-2035 (USD Billion) | |
  2. 7.24.2 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
  3. 7.24.3 BY SERVICE TYPE, 2025-2035 (USD Billion) | |
  4. 7.24.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.24.5 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) |
171. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.25.1 BY ONCOLOGY TYPE, 2025-2035 (USD Billion) | |
  2. 7.25.2 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
  3. 7.25.3 BY SERVICE TYPE, 2025-2035 (USD Billion) | |
  4. 7.25.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.25.5 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) |
172. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.26.1 BY ONCOLOGY TYPE, 2025-2035 (USD Billion) | |
  2. 7.26.2 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
  3. 7.26.3 BY SERVICE TYPE, 2025-2035 (USD Billion) | |
  4. 7.26.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.26.5 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) |
173. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.27.1 BY ONCOLOGY TYPE, 2025-2035 (USD Billion) | |
  2. 7.27.2 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
  3. 7.27.3 BY SERVICE TYPE, 2025-2035 (USD Billion) | |
  4. 7.27.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.27.5 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) |
174. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.28.1 BY ONCOLOGY TYPE, 2025-2035 (USD Billion) | |
  2. 7.28.2 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
  3. 7.28.3 BY SERVICE TYPE, 2025-2035 (USD Billion) | |
  4. 7.28.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.28.5 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) |
175. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.29.1 BY ONCOLOGY TYPE, 2025-2035 (USD Billion) | |
  2. 7.29.2 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
  3. 7.29.3 BY SERVICE TYPE, 2025-2035 (USD Billion) | |
  4. 7.29.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.29.5 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) |
176. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.30.1 BY ONCOLOGY TYPE, 2025-2035 (USD Billion) | |
  2. 7.30.2 BY ANIMAL TYPE, 2025-2035 (USD Billion) | |
  3. 7.30.3 BY SERVICE TYPE, 2025-2035 (USD Billion) | |
  4. 7.30.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.30.5 BY DIAGNOSTIC METHOD, 2025-2035 (USD Billion) |
177. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
  1. 7.31.1 |
178. 7.32 ACQUISITION/PARTNERSHIP | |

Certified Researchers

Customize Report

Healthcare Market Segmentation

Healthcare By Oncology Type (USD Billion, 2025-2035)

Surgery
Radiation Therapy
Chemotherapy
Immunotherapy
Targeted Therapy

Healthcare By Animal Type (USD Billion, 2025-2035)

Dogs
Cats
Horses
Small Mammals
Exotic Animals

Healthcare By Service Type (USD Billion, 2025-2035)

Diagnosis
Treatment
Palliative Care
Preventive Care

Healthcare By End User (USD Billion, 2025-2035)

Veterinary Clinics
Animal Hospitals
Research Institutions

Healthcare By Diagnostic Method (USD Billion, 2025-2035)

Biopsy
Blood Tests
Imaging Techniques
Endoscopy

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Features	License Type
Features	Single User	Multiuser License	Enterprise User
Price	$4,950	$5,950	$7,250
Maximum User Access Limit	1 User	Upto 10 Users	Unrestricted Access Throughout the Organization
Free Customization	✓	✓	✓
Direct Access to Analyst	✓	✓	✓
Deliverable Format	✓	✓	✓
Platform Access	✗	✗	✓
Discount on Next Purchase	10%	15%	15%
Printable Versions	✗	✗	✓